Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

We previously reported a phase 1b dose-escalation study of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in relapsed or progressive multiple myeloma where the maximum planned dose (MPD) was carfilzomib 20 mg/m(2) days 1 and 2 of cycle 1 and 27 mg/m(2) days 8, 9, 15, 16, and thereafter;...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Wang, Michael, Martin, Tom, Bensinger, William, Alsina, Melissa, Siegel, David S., Kavalerchik, Edward, Huang, Mei, Orlowski, Robert Z., Niesvizky, Ruben
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2013
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3814729/
https://ncbi.nlm.nih.gov/pubmed/24014245
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-07-511170
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky